Subscribe To

Price Alert Latest News Economic Calendar News

TBPH / Wall Street Analysts Think Theravance Bio (TBPH) Could Surge 27%: Read This Before Placing a Bet

The mean of analysts' price targets for Theravance Bio (TBPH) points to a 26.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. Read More

Demo Live Account See Partner Details

Content Topics

Zibo

Qixiang

Tengda

Chemical

Co

Ltd

002408

Sz

Street

Analysts

Theravance

tbph

Before

Placing

Stock

TBPH

Posted: Feb 18 2022, 11:39

Author Name: Zacks Investment Research

TBPH News

By Seeking Alpha
September 9, 2023

Theravance: Positive Findings Boost Ampreloxetine Development

Theravance Biopharma has a diversified portfolio in the healthcare sector, with the potential for high returns and risk mitigation. The company's fina

By Seeking Alpha
September 8, 2023

Theravance Biopharma: YUPELRI Numbers Don't Substantiate 9x Forward Sales, Rate Hold

Theravance Biopharma has pushed into congestion in 2023, backing and filling throughout the year. Its YUPELRI label offers targeted bronchodilation fo

By PRNewsWire
August 28, 2023

Theravance Biopharma to Present New Ampreloxetine Data at the 2023 International Congress of Parkinson's Disease and Movement Disorders

DUBLIN , Aug. 28, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced new amprel

By Zacks Investment Research
August 8, 2023

Theravance's (TBPH) Q2 Earnings Beat Estimates, Revenues Miss

Thervance's (TBPH) second-quarter 2023 loss is narrower than expected. Revenues rise year over year.

By Seeking Alpha
August 7, 2023

Theravance Biopharma, Inc. (TBPH) Q2 2023 Earnings Call Transcript

Theravance Biopharma, Inc. (NASDAQ:TBPH ) Q2 2023 Earnings Conference Call August 7, 2023 5:00 PM ET Company Participants Rick Winningham - Chief Exec

By Zacks Investment Research
August 7, 2023

Theravance Biopharma (TBPH) Reports Q2 Loss, Lags Revenue Estimates

Theravance Biopharma (TBPH) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to

By Seeking Alpha
May 3, 2023

Theravance Biopharma: Activist Pressure Might Lead To Substantial Capital Return

Theravance Biopharma has recently come under pressure from a reputable activist investor, Irenic Capital. The activist is pushing the company to initi

By PRNewsWire
April 10, 2023

Theravance Biopharma to Participate in an Upcoming Investor Conference

DUBLIN , April 10, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will present at the 22nd Annual Needham Virtual Healthcare Conferenc

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.